Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HEMANT PANDEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1275535403
CMS profile
284264
Location
CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,992.81

149 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,250.00 1
Food and Beverage $2,652.82 147
Education $89.99 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HEMANT PANDEY

NPI 1275535403 · CMS profile ID 284264

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHANDLER, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275535403?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HEMANT PANDEY, NPI 1275535403, CMS profile ID 284264. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275535403?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HEMANT PANDEY, NPI 1275535403, CMS profile ID 284264. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275535403?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HEMANT PANDEY, NPI 1275535403, CMS profile ID 284264, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1275535403?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

149 matching records · $7,992.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 149 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 149.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $30.8808/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016998269 CMS
PFIZER INC. $16.2708/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049873049 CMS
UCB, Inc. $20.8407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021445753 CMS
Lilly USA, LLC $13.9707/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031505801 CMS
Lundbeck LLC $19.7307/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032309087 CMS
PFIZER INC. $14.0207/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049988461 CMS
ABBVIE INC. $12.9307/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066075 CMS
ABBVIE INC. $12.5607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066077 CMS
UCB, Inc. $32.4707/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021445777 CMS
UCB, Inc. $2.2507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021453155 CMS
UCB, Inc. $3.8807/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021453173 CMS
Kyowa Kirin, Inc. $19.4507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026997025 CMS
Lilly USA, LLC $27.7807/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031692931 CMS
UCB, Inc. $17.5907/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021445731 CMS
UCB, Inc. $3.7407/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021453171 CMS
GENZYME CORPORATION $27.9907/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049955729 CMS
Horizon Therapeutics plc $16.6607/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987055243 CMS
SK Life Science, Inc. $26.2507/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054767585 CMS
Amneal Pharmaceuticals LLC $19.5607/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053522809 CMS
IMPEL PHARMACEUTICALS INC. $23.1407/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989374497 CMS
ABBVIE INC. $3.9406/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066073 CMS
Teva Pharmaceuticals USA, Inc. $32.4106/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056878321 CMS
UCB, Inc. $25.6406/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021445763 CMS
UCB, Inc. $0.5106/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021457111 CMS
ABBVIE INC. $24.5906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066071 CMS
Otsuka America Pharmaceutical, Inc. $18.2506/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014663385 CMS
ABBVIE INC. $24.2106/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066069 CMS
Lilly USA, LLC $18.7706/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031487961 CMS
SK Life Science, Inc. $19.9706/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054767569 CMS
ABBVIE INC. $17.6306/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066067 CMS
Avion Pharmaceuticals $24.3705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032970685 CMS
Lundbeck LLC $25.1705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032309079 CMS
Sumitomo Pharma America, Inc. $7.9105/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030814673 CMS
ABBVIE INC. $25.1805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066063 CMS
ABBVIE INC. $1.6005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066065 CMS
Lilly USA, LLC $15.0305/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031487957 CMS
ARGENX US, INC. $21.0805/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060397067 CMS
Eisai Inc. $20.1705/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023312495 CMS
UCB, Inc. $34.6705/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021445779 CMS
Amneal Pharmaceuticals LLC $25.7405/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053522803 CMS
ABBVIE INC. $8.7105/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066061 CMS
UCB, Inc. $30.4705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021445767 CMS
UCB, Inc. $3.6105/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021453167 CMS
Otto Bock HealthCare LP $24.0705/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989024161 CMS
Grifols USA, LLC $20.5405/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011765943 CMS
Teva Pharmaceuticals USA, Inc. $15.0705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056878295 CMS
Alexion Pharmaceuticals, Inc. $22.4305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017018419 CMS
ABBVIE INC. $6.2005/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066059 CMS
ABBVIE INC. $10.4304/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066057 CMS
ABBVIE INC. $12.4504/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998066055 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,589.59 145
PY2020 $3,700.82 33
PY2021 $14,408.52 52
PY2022 $6,906.36 74
PY2023 $7,992.81 149
PY2024 $48,800.61 185
PY2025 $139,285.59 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,672,634.33 84
PY2024 Recipient $8.40 1
PY2024 Principal investigator $1,181,050.55 24
PY2023 Recipient $8,223.73 2
PY2023 Principal investigator $1,216,125.05 17
PY2022 Recipient $39,234.00 2
PY2022 Principal investigator $89,899.25 16
PY2021 Principal investigator $199,534.62 32
PY2020 Principal investigator $188,552.62 30
PY2019 Recipient $85.79 1
PY2019 Principal investigator $415,045.05 189

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
MD FIRST RESEARCH CHANDLER LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202532434
Principal investigator 1 ABBVIE INC. $8,592.59 12/04/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528488
Principal investigator 1 Ipsen Innovation $2,327.65 12/01/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296313
Principal investigator 1 Ipsen Innovation $1,054.09 12/01/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296315
Principal investigator 1 Ipsen Innovation $1,054.09 12/01/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296317
Principal investigator 1 ABBVIE INC. $11,997.72 11/05/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521345
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296267
Principal investigator 1 Ipsen Innovation $2,703.31 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296269
Principal investigator 1 Ipsen Innovation $4,101.06 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296271
Principal investigator 1 Ipsen Innovation $2,327.65 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296273
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296275
Principal investigator 1 Ipsen Innovation $4,101.06 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296277
Principal investigator 1 Ipsen Innovation $2,516.21 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296279
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296281
Principal investigator 1 Ipsen Innovation $2,248.59 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296283
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296285
Principal investigator 1 Ipsen Innovation $2,054.01 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296287
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296289
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296291
Principal investigator 1 Ipsen Innovation $4,101.06 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296293
Principal investigator 1 Ipsen Innovation $4,101.06 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296295
Principal investigator 1 Ipsen Innovation $4,101.06 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296297
Principal investigator 1 Ipsen Innovation $2,248.59 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296299
Principal investigator 1 Ipsen Innovation $2,703.31 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296301
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296303
Principal investigator 1 Ipsen Innovation $3,225.45 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296305
Principal investigator 1 Ipsen Innovation $1,054.09 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296307
Principal investigator 1 Ipsen Innovation $4,101.06 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296309
Principal investigator 1 Ipsen Innovation $2,516.21 10/22/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296311
Principal investigator 1 Ipsen Innovation $1,054.09 09/29/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296265
Principal investigator 1 Eli Lilly and Company $205,668.92 09/23/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187884742
Principal investigator 1 Ipsen Innovation $126.00 08/19/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296263
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,100.00 08/08/2025 Non-covered Recipient Entity
Mdfirst Research
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235995955
Principal investigator 1 ABBVIE INC. $2,125.68 08/06/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202502957
Principal investigator 1 Ipsen Innovation $1,002.68 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296237
Principal investigator 1 Ipsen Innovation $2,452.38 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296239
Principal investigator 1 Ipsen Innovation $1,002.68 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296241
Principal investigator 1 Ipsen Innovation $1,002.68 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296243
Principal investigator 1 Ipsen Innovation $2,452.38 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296245
Principal investigator 1 Ipsen Innovation $1,002.68 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296247
Principal investigator 1 Ipsen Innovation $2,023.30 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296249
Principal investigator 1 Ipsen Innovation $3,354.32 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296251
Principal investigator 1 Ipsen Innovation $2,023.30 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296253
Principal investigator 1 Ipsen Innovation $1,002.68 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296255
Principal investigator 1 Ipsen Innovation $2,217.88 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296257
Principal investigator 1 Ipsen Innovation $2,639.48 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296259
Principal investigator 1 Ipsen Innovation $3,354.32 07/30/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296261
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $11,700.00 07/11/2025 Non-covered Recipient Entity
Mdfirst Research Chandler Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066995
Principal investigator 1 ABBVIE INC. $18,842.33 07/02/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202495943
Principal investigator 1 Eli Lilly and Company $6.72 05/16/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187884242
Principal investigator 1 ABBVIE INC. $13,850.05 05/07/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482537
Principal investigator 1 Ipsen Innovation $3,354.32 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296205
Principal investigator 1 Ipsen Innovation $4,149.01 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296207
Principal investigator 1 Ipsen Innovation $2,023.30 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296209
Principal investigator 1 Ipsen Innovation $2,217.88 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296211
Principal investigator 1 Ipsen Innovation $1,002.68 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296213
Principal investigator 1 Ipsen Innovation $2,639.48 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296215
Principal investigator 1 Ipsen Innovation $2,217.88 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296217
Principal investigator 1 Ipsen Innovation $2,023.30 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296219
Principal investigator 1 Ipsen Innovation $4,149.01 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296221
Principal investigator 1 Ipsen Innovation $1,002.68 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296223
Principal investigator 1 Ipsen Innovation $4,149.01 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296225
Principal investigator 1 Ipsen Innovation $4,149.01 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296227
Principal investigator 1 Ipsen Innovation $3,354.32 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296229
Principal investigator 1 Ipsen Innovation $2,639.48 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296231
Principal investigator 1 Ipsen Innovation $1,002.68 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296233
Principal investigator 1 Ipsen Innovation $4,149.01 04/28/2025 Non-covered Recipient Entity
Trialsphere Clinical Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184296235
Principal investigator 1 ABBVIE INC. $7,350.00 04/17/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202477573
Principal investigator 1 ABBVIE INC. $5,744.82 04/03/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202472206
Principal investigator 1 Eli Lilly and Company $492.50 03/25/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187885838
Principal investigator 1 ABBVIE INC. $213.90 03/24/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202465524
Principal investigator 1 ABBVIE INC. $62.50 03/24/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202465528
Principal investigator 1 Eli Lilly and Company $1,022,268.66 03/10/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187886806
Principal investigator 1 ABBVIE INC. $2,872.41 03/07/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202461527
Principal investigator 1 Eli Lilly and Company $329,536.00 02/11/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885778
Principal investigator 1 Eli Lilly and Company $343,030.00 02/04/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187885776
Principal investigator 1 Eli Lilly and Company $544.18 01/31/2025 Non-covered Recipient Entity
MDFIRST RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187886808
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,482.86 01/27/2025 Non-covered Recipient Entity
MD First Research - Chandler
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995959
Principal investigator 1 Eli Lilly and Company $10,527.05 01/27/2025 Non-covered Recipient Entity
MDFIRST RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187884744
Principal investigator 1 Eli Lilly and Company $1,427.95 01/27/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885840
Principal investigator 1 Eli Lilly and Company $49,163.00 01/21/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885144
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $274,912.75 01/16/2025 Non-covered Recipient Entity
MD First Research - Chandler
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995957
Principal investigator 1 Eli Lilly and Company $194,975.00 01/07/2025 Non-covered Recipient Entity
MDFIRST RESEARCH CHANDLER LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1187886804
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,594.60 01/07/2025 Non-covered Recipient Entity
MDFIRST RESEARCH
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190310635